Clinical practice guideline for the treatment of hormone-sensitive metastatic prostate cancer in the Peruvian Social Security (EsSalud)
DOI:
https://doi.org/10.35434/rcmhnaaa.2023.164.2049Keywords:
Prostatic Neoplasms, Neoplasm Metastasis, Practice Guidelines as Topic, GRADE Approach, Evidence-Based MedicineAbstract
Introduction: This article summarizes the clinical practice guideline (CPG) for the treatment of metastatic hormone-sensitive prostate cancer in the Social Security of Peru (EsSalud). Objective: To provide evidence-based clinical recommendations for the treatment of adults with hormone-sensitive metastatic adenocarcinoma of the prostate with de novo or recurrent presentation and high or low metastatic volume in EsSalud. Methods: A guideline development group (GDG) was formed, which included specialist physicians and methodologists, who formulated clinical questions. Systematic searches were conducted for systematic reviews and - when deemed relevant - primary studies in PubMed during 2022. Evidence was selected to answer each of the clinical questions posed. The certainty of evidence was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. In periodic working meetings, the GEG used the GRADE methodology to review the evidence and formulate recommendations. The CPG was reviewed by external experts before its approval. Results: The CPG addressed 6 clinical questions, divided into 2 main topics: considerations on androgen deprivation therapy (ADT) and ADT combined with other therapies. Based on these questions, 10 recommendations were formulated (4 strong and 6 conditional), and 6 points of good clinical practice. Conclusion: Evidence-based recommendations were issued for the management of patients with this pathology.
Downloads
Metrics
References
Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE, et al. Prostate cancer. Nat Rev Dis Primer. 4 de febrero de 2021;7(1):1-27.
Instituto Nacional de Enfermedades Neoplásicas. INEN Ilumina su Fachada de Azul por el Mes Internacional de la Lucha Contra el Cáncer de Próstata [Internet]. Lima: INEN; 2023 [citado 22 dic 2023]. Disponible en: https://portal.inen.sld.pe/inen-ilumina-su-fachada-de-azul-por-el-mes-internacional-de-la-lucha-contra-el-cancer-de-prostata-2/
Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. The Lancet. 18 de septiembre de 2021;398(10305):1075-90.
Sayegh N, Swami U, Agarwal N. Recent Advances in the Management of Metastatic Prostate Cancer. JCO Oncol Pract. enero de 2022;18(1):45-55.
Ng K, Smith S, Shamash J. Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting. Oncol Ther. 15 de junio de 2020;8(2):209-30.
Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, et al. Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci. 2021;112(4):1524-33.
AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both | The BMJ [Internet]. [citado 27 de mayo de 2023]. Disponible en: https://www.bmj.com/content/358/bmj.j4008.long
Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation’s direction and strength. J Clin Epidemiol. 1 de julio de 2013;66(7):726-35.
Alonso-Coello P, Schünemann HJ, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction. BMJ. 28 de junio de 2016;353:i2016.
Alonso-Coello P, Oxman AD, Moberg J, Brignardello-Petersen R, Akl EA, Davoli M, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ. 30 de junio de 2016;353:i2089.
Liu M, Qu S, Liu Y, Yao X, Jiang W. Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China. J Comp Eff Res. agosto de 2019;8(11):865-77.
Yang Y, Chen R, Sun T, Zhao L, Liu F, Ren S, et al. Efficacy and safety of combined androgen blockade with antiandrogen for advanced prostate cancer. Curr Oncol. febrero de 2019;26(1):e39-47.
Wu J, Chen WK, Zhang W, Zhang JS, Liu JH, Jiang YM, et al. Network meta-analysis of the efficacy and adverse effects of several treatments for advanced/metastatic prostate cancer. Oncotarget. 2 de agosto de 2017;8(35):59709-19.
Samson DJ, Seidenfeld J, Schmitt B, Hasselblad V, Albertsen PC, Bennett CL, et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer. 15 de julio de 2002;95(2):361-76.
Schmitt B, Wilt TJ, Schellhammer PF, DeMasi V, Sartor O, Crawford ED, et al. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review. Urology. abril de 2001;57(4):727-32.
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. The Lancet. 29 de abril de 2000;355(9214):1491-8.
Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis. enero de 1999;2(1):4-8.
Seidenfeld J, Samson DJ, Aronson N, Albertson PC, Bayoumi AM, Bennett C, et al. Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). mayo de 1999;(4):i-passim.
Caubet JF, Tosteson TD, Dong EW, Naylon EM, Whiting GW, Ernstoff MS, et al. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology. 1 de enero de 1997;49(1):71-8.
Kunath F, Jensen K, Pinart M, Kahlmeyer A, Schmidt S, Price CL, et al. Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer. Cochrane Database Syst Rev. 11 de junio de 2019;2019(6):CD003506.
Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-Therapy Androgen Suppression in Men with Advanced Prostate Cancer. Ann Intern Med. 4 de abril de 2000;132(7):566-77.
Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 1 de diciembre de 2015;1(9):1261-9.
Brungs D, Chen J, Masson P, Epstein RJ. Intermittent androgen deprivation is a rational standard-of-care treatment for all stages of progressive prostate cancer: results from a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. junio de 2014;17(2):105-11.
Botrel TEA, Clark O, dos Reis RB, Pompeo ACL, Ferreira U, Sadi MV, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol. 25 de enero de 2014;14:9.
Tsai HT, Penson DF, Makambi KH, Lynch JH, Eeden SKVD, Potosky AL. Efficacy of Intermittent Androgen Deprivation Therapy vs Conventional Continuous Androgen Deprivation Therapy for Advanced Prostate Cancer: A Meta-analysis. Urology. 1 de agosto de 2013;82(2):327-34.
Weiner AB, Siebert AL, Fenton SE, Abida W, Agarwal N, Davis ID, et al. First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. Eur Urol Oncol. 1 de agosto de 2022;5(4):377-87.
Menges D, Yebyo HG, Sivec-Muniz S, Haile SR, Barbier MC, Tomonaga Y, et al. Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment. Eur Urol Oncol. 1 de diciembre de 2022;5(6):605-16.
Mori K, Mostafaei H, Sari Motlagh R, Pradere B, Quhal F, Laukhtina E, et al. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis. BJU Int. 2022;129(4):423-33.
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, et al. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer Prostatic Dis. junio de 2022;25(2):139-48.
Wang L, Paller CJ, Hong H, De Felice A, Alexander GC, Brawley O. Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. JAMA Oncol. 1 de marzo de 2021;7(3):412-20.
Ferro M, Lucarelli G, Crocetto F, Dolce P, Verde A, La Civita E, et al. First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. Crit Rev Oncol Hematol. enero de 2021;157:103198.
Wang Y, Gui H, Wang J, Tian J, Wang H, Liang C, et al. Comparative Efficacy of Combined Radiotherapy, Systemic Therapy, and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Network Meta-Analysis and Systematic Review. Front Oncol [Internet]. 2020 [citado 27 de mayo de 2023];10. Disponible en: https://www.frontiersin.org/articles/10.3389/fonc.2020.567616
Chen J, Ni Y, Sun G, Liao B, Zhang X, Zhao J, et al. Comparison of Current Systemic Combination Therapies for Metastatic Hormone-Sensitive Prostate Cancer and Selection of Candidates for Optimal Treatment: A Systematic Review and Bayesian Network Meta-Analysis. Front Oncol [Internet]. 2020 [citado 27 de mayo de 2023];10. Disponible en: https://www.frontiersin.org/articles/10.3389/fonc.2020.519388
Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G, et al. Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. 1 de marzo de 2020;77(3):365-72.
Sathianathen NJ, Philippou YA, Kuntz GM, Konety BR, Gupta S, Lamb AD, et al. Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer: a Cochrane Review. BJU Int. 2019;124(3):370-2.
Sun G, Zhang X, Chen J, Liao B, Liu Z, Zhao J, et al. What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis. Urol Oncol Semin Orig Investig. 1 de diciembre de 2018;36(12):505-17.
Tan PS, Aguiar P, Haaland B, Lopes G. Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. Prostate Cancer Prostatic Dis. 1 de noviembre de 2018;21(4):516-23.
Vale CL, Fisher DJ, White IR, Carpenter JR, Burdett S, Clarke NW, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 1 de mayo de 2018;29(5):1249-57.
Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, et al. Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis. Eur Urol. 1 de julio de 2019;76(1):115-24.
Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI). Resolución N°12-IETSI-2023. Lima: EsSalud.; 2023 [citado el 21 de mayo de 2023]. Disponible en: https://ietsi.essalud.gob.pe/wp-content/uploads/2023/02/RESOLUCION-N%C2%B0-12-IETSI-2023-APREPITANT-125MG-Y-ACETATO-DE-ABIRATERONA-250MG.pdf.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Nelson Cuevas-Muñoz , Oswaldo Broncano-Huasasquiche , Sergio Goicochea-Lugo , Carolina J. Delgado-Flores , Alvaro Taype-Rondan , Eliana L. Fernandez-Quiroz , Teofilo Livano Yberico , Mariano Cuentas-Jara, Abel Cordier-Mariaca, Luís Alberto Velarde-Ponce, Jesús Delgado-Iriarte, Stefany Salvador-Salvador , Vladimir Santos-Sánchez
This work is licensed under a Creative Commons Attribution 4.0 International License.
